Tenax Therapeutics (TENX) Says Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint

January 31, 2017 9:03 AM EST Send to a Friend
Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login